CELLECTIS SA Sues Precision BioSciences for Infringement of Its Patents Concerning Meganuclease Technology
The Precision Biosciences’ meganucleases at issue are intended to target site-specific DNA breaks and effect a desired genome modification in a given transgenic organism, such as a plant. The lawsuit seeks both monetary damages for infringement, as well as a permanent injunction preventing Precision BioSciences from any further making, using or selling of such meganucleases.
“We take our intellectual property rights very seriously and intend to vigorously pursue this patent infringement case,” said Dr. André Choulika, CEO and co-founder of Cellectis SA., and the man who participated in coining the term “meganuclease.”
Caroline Carmagnol ALIZE RP + 33 6 64 18 99 59 + 33 141 22 07 31